

REMARKS

By this amendment, claims 26 and 77 have been amended. Claims 27-29, 31, and 71 have been canceled. Claims 78-82 have been added. Claims 26 and 77-82 are pending in the application. Applicants reserve the right to pursue the original claims and other claims in this and other applications.

Applicant notes that an IDS was filed on February 16, 2006 and requests that the cited references be expressly considered.

The amendment filed November 17, 2005 stands objected to under 35 U.S.C. §132(a) for containing new matter and claims 26 and 77 stand rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement because claims 26 and 77 contain the phrase "consisting essentially of". The phrase "consisting essentially of" has been removed to obviate the Examiner's concerns.

Claims 26 and 77 stand rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 4,857,140 ("Lowenstein"). The rejection is respectfully traversed.

Claim 26 as amended recites, *inter alia*, "wherein said at least two fluorocarbons are selected from the group consisting of fluorohydrocarbons, chlorofluorocarbons, and chlorofluorohydrocarbons." Lowenstein does not disclose this limitation. To the contrary, Lowenstein discloses only one type of fluorohydrocarbon (CHF₃, column 5, line 24) and no chlorofluorocarbons or chlorofluorohydrocarbons. Therefore, Lowenstein cannot teach that "two fluorocarbons are selected from the group consisting of fluorohydrocarbons, chlorofluorocarbons, and chlorofluorohydrocarbons." Since Lowenstein does not disclose all the limitations of claim 26, claim 26 is not anticipated by Lowenstein. Claim 82 depends from claim 26

and is patentable at least for the reasons mentioned above. Applicants respectfully request that the 35 U.S.C. § 102(b) rejection of claims 26 and 82 be withdrawn.

Claim 77 as amended recites, *inter alia*, “[a] plasma etching composition consisting essentially of: at least one fluorocarbon, oxygen, and ammonia”. Lowenstein does not disclose a plasma etching composition that includes oxygen. Since Lowenstein does not disclose all the limitations of claim 77, claim 77 is not anticipated by Lowenstein. Applicants respectfully request that the 35 U.S.C. § 102(b) rejection of claim 77 be withdrawn.

In view of the above amendment, applicant believes the pending application is in condition for allowance.

Dated: May 10, 2006

Respectfully submitted,

By 
Thomas J. D'Amico

Registration No.: 28,371
DICKSTEIN SHAPIRO MORIN &
OSHINSKY LLP
2101 L Street NW
Washington, DC 20037-1526
(202) 785-9700
Attorney for Applicant